Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Ally Bridge Group (NY) LLC

Q4 2023 · 13F-HR

Ally Bridge Group (NY) LLCholdings as filed

Filed 2024-02-14 · accession 0000950123-24-002153

$167.8M
Reported value
22
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
471871103JASPER THERAPEUTICS INC$28.9M17.2%3,659,255CommonSOLE
04016X101ARGXARGENX SE - ADR$13.3M7.93%35,000CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$12.5M7.43%309,950CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$11.6M6.90%489,938CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$11.1M6.64%241,961CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC$10.1M6.03%141,348CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$9.2M5.51%659,035CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$9.0M5.35%150,000CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$8.7M5.16%143,479CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$8.0M4.78%100,862CommonSOLE
N5749R1002GHMERUS NV$7.6M4.50%274,923CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$6.8M4.06%357,271CommonSOLE
374163103GERNGERON CORP$6.3M3.74%2,971,639CommonSOLE
641871108AMBRX BIOPHARMA INC$5.5M3.27%385,383CommonSOLE
05337M104AVADEL PHARMACEUTICALS-ADR$4.9M2.92%347,036CommonSOLE
41358P205HARPUSDHARPOON THERAPEUTICS INC$4.9M2.90%428,400CommonSOLE
03237H101AMLXAMYLYX PHARMACEUTICALS INC$4.1M2.42%275,773CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$1.6M0.93%70,424CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$1.3M0.78%834,630CommonSOLE
74346M406PMNEURPROMIS NEUROSCIENCES INC$1.2M0.73%1,066,674CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$820,3250.49%725,951CommonSOLE
58406B202MDVLQMEDAVAIL HOLDINGS INC$529,3580.32%117,897CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.